Depressive spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review
Depressive spectrum disorders in cancer: prevalence, risk factors and screening for depression: a critical review
复制标题
DOI：
10.1080/0284186x.2016.1266090
复制
发表时间：
2017-02-01
期刊：
影响因子：
3.1
通讯作者：
Grassi, L.
中科院分区：
文献类型：
--
作者：
Caruso, R.;Nanni, M. G.;Grassi, L.
背景：尽管抑郁症和情绪相关疾病在癌症患者中很常见，但这些病症在临床实践中仍然经常被忽视。抑郁症谱系的负面后果已有报道（例如自杀意念、身体并发症和躯体症状增加、对预后产生负面影响），这表明需要进行常规筛查、评估和管理。方法：对主要数据库（Medline、Embase、PsycLIT、PsycINFO 和 Cochrane 图书馆）进行检索，对可用的综述和荟萃分析进行检索，以总结抑郁症谱系在患病率、危险因素以及筛查和治疗方面的相关数据。结果：数据显示，根据不同的诊断标准、研究中使用的工具（例如半结构化精神病学访谈和心理测量问卷）以及癌症的阶段和类型，抑郁症和抑郁症的患病率在 5% 至 60% 之间。此外，尽管投入了大量的医疗资源用于癌症治疗，并且解决抑郁症状也很重要，但癌症患者抑郁谱系障碍的评估和管理仍然不够理想。结论：为了有效管理癌症治疗的多方面和复杂后果，对癌症患者进行抑郁谱系障碍的常规筛查和充分评估是必要的。
Background: Although depression and mood-related disorders are common in persons with cancer, these conditions remain frequently overlooked in clinical practice. Negative consequences of depressive disorder spectrum have been reported (e.g. suicidal ideation, increase physical complications and somatic symptoms, negative influence on prognosis), indicating the need for routine screening, assessment and management.Methods: A search of the major databases (Medline, Embase, PsycLIT, PsycINFO, and the Cochrane Library) was conducted on the reviews and meta-analyses available in order to summarize relevant data concerning depressive disorders spectrum in terms of prevalence, risk factors, and screening and assessment among patients with cancer across the trajectory of the disease.Results: The data show a prevalence of depression and depressive disorders between 5% and 60% according to the different diagnostic criteria, the tools used in the studies (e.g. semi-structured psychiatric interview and psychometric questionnaires), as well as the stage and type of cancer. Furthermore, despite the significant health care resources devoted to cancer care and the importance of addressing depressive symptoms, assessment and management of depressive spectrum disorders in cancer patients remains suboptimal.Conclusions: Routine screening and adequate assessment of depressive spectrum disorders is necessary in patients with cancer in order to effectively manage the multifaceted and complex consequences on cancer care.